Stockreport

Regeneron's R&D approach scores dual wins against Alexion's Ultomiris and in lymphoma [Yahoo! Finance]

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF outperforming Alexion's Ultomiris in a head-to-head trial for the rare blood disorder paroxysmal nocturnal hemoglobinuria, and its bispecific antibody Ordspono achieving [Read more]